Jan 8, 2023
ExoProTher at JP Morgan Healthcare Conference Week
ExoProTher takes part in JP Morgan week in San Francisco as part of Israeli Health Innovation Delegation organized by California Israel Chamber of Commerce (CICC).
Jan 4, 2023
ExoProTher Podcast - OutcomesRocket
The origin of our anti-cancer treatment - ExoProTher Medical on OutcomesRocket
30 seconds about the origin of our anti-cancer treatment.
Sep 26, 2022
ExoProTher CTO Pitch San Diego
ExoProTher Medical : CTO Dr. Alex Tendler : Latest updates
Rosh-HaShanah : San Diego
Hosted by #Shay Wail
Video of the event:
Dec 30, 2021
Israel Biotech Fund
We are excited to step into 2022 together with IBF
Proud to be part of exclusive portfolio of innovative #lifesciences companies.
This funding accelerates the path towards clinical stage of our first-in-class biotherapy targeting cancers with p53 mutations.
We are on mission to bring cure to cancer patients.
Dec 11, 2021
Virtual MedInvest Oncology Investor Conference
This week ExoProTher Medical presented at the virtual MedInvest Oncology Investor Conference. ExoProTher’s Chief Executive Officer, Lana Volokh, delivered the corporate overview. She described the Company’s unique scientific foundation and technology and provided an update on program status. ExoProTher aims to significantly impact the way cancer is treated. Link to the presentation recording: https://youtu.be/JxwwiSTyrwk
Jun 23, 2021
New R&D lab at Colab Square Facility, Yokneam
Beginning May 2021, ExoProTher is operating a new R&D lab situated at unique Colab Square facility in Yokneam Industrial park. ExoProTher is joining a line of exciting and promising biotech companies.
The combination of location, equipment and environment allow to boost R&D activities and attract top talent to the expanding team.
Nov 11, 2020
ExoProTher milestone achieved
I am pleased to share with our followers and investors the latest in vivo results.
Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.
Lana Volokh - CEO
Sep 12, 2020
New recruits & Additional facility
Exciting growth period for ExoProTher Medical: we opened a new laboratory facility and brought on board new talent.
The new laboratory started functioning in Shlomi, Israel. It will focus on optimizing production and characterization of EXO_ compounds.
With extended R&D team, we continue to broaden and deepen our research capabilities.